Clinical evaluation of tumor scanning with 57Co-bleomycin

Tumor scanning with 57Co-bleomycin was carried out in 46 patients with an overall accuracy of G6% in malignant tumors. There were no genuine false positive results in four benign lesions. Since 57Co-bleomycin is excreted rapidly through the kidneys, a high tumor-to-blood ratio is obtained a short time after injection. Although its long physical half-life may restrict its routine use, 57Co-bleomycin might provide a valuable adjunct in the work-up of malignant tumors when used in properly selected patients.